These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 27965422)

  • 1. Circulating ACE2 activity correlates with cardiovascular disease development.
    Úri K; Fagyas M; Kertész A; Borbély A; Jenei C; Bene O; Csanádi Z; Paulus WJ; Édes I; Papp Z; Tóth A; Lizanecz E
    J Renin Angiotensin Aldosterone Syst; 2016 Oct; 17(4):. PubMed ID: 27965422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure.
    Úri K; Fagyas M; Mányiné Siket I; Kertész A; Csanádi Z; Sándorfi G; Clemens M; Fedor R; Papp Z; Édes I; Tóth A; Lizanecz E
    PLoS One; 2014; 9(4):e87845. PubMed ID: 24691269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of ACE2-Ang (1-7)-Mas receptor axis in heart failure with preserved ejection fraction with hypertension].
    Yu J; Wu Y; Zhang Y; Zhang L; Ma Q; Luo X
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Jul; 43(7):738-746. PubMed ID: 30124209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker Profiles in Heart Failure Patients With Preserved and Reduced Ejection Fraction.
    Tromp J; Khan MA; Klip IT; Meyer S; de Boer RA; Jaarsma T; Hillege H; van Veldhuisen DJ; van der Meer P; Voors AA
    J Am Heart Assoc; 2017 Mar; 6(4):. PubMed ID: 28360225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
    Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
    Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between circulating angiotensin-converting enzyme 2 and cardiac remodeling in hypertensive patients.
    Li S; Wang Z; Yang X; Hu B; Huang Y; Fan S
    Peptides; 2017 Apr; 90():63-68. PubMed ID: 28223093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
    Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
    Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
    Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
    Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study.
    Kontogeorgos S; Thunström E; Johansson MC; Fu M
    Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system.
    Epelman S; Tang WH; Chen SY; Van Lente F; Francis GS; Sen S
    J Am Coll Cardiol; 2008 Aug; 52(9):750-4. PubMed ID: 18718423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomic fingerprint of heart failure with preserved ejection fraction.
    Zordoky BN; Sung MM; Ezekowitz J; Mandal R; Han B; Bjorndahl TC; Bouatra S; Anderson T; Oudit GY; Wishart DS; Dyck JR;
    PLoS One; 2015; 10(5):e0124844. PubMed ID: 26010610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating angiotensin-converting enzyme 2 activity in kidney transplantation: a longitudinal pilot study.
    Soler MJ; Riera M; Crespo M; Mir M; Márquez E; Pascual MJ; Puig JM; Pascual J
    Nephron Clin Pract; 2012; 121(3-4):c144-50. PubMed ID: 23257682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme.
    Damman K; Solomon SD; Pfeffer MA; Swedberg K; Yusuf S; Young JB; Rouleau JL; Granger CB; McMurray JJ
    Eur J Heart Fail; 2016 Dec; 18(12):1508-1517. PubMed ID: 27427441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization.
    Hisatake S; Kiuchi S; Kabuki T; Oka T; Dobashi S; Ikeda T
    Heart Vessels; 2017 Mar; 32(3):303-308. PubMed ID: 27421979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.
    Sanders-van Wijk S; van Empel V; Davarzani N; Maeder MT; Handschin R; Pfisterer ME; Brunner-La Rocca HP;
    Eur J Heart Fail; 2015 Oct; 17(10):1006-14. PubMed ID: 26472682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin.
    Faxén UL; Hage C; Andreasson A; Donal E; Daubert JC; Linde C; Brismar K; Lund LH
    Int J Cardiol; 2017 Feb; 228():709-716. PubMed ID: 27886615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
    Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
    Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of chronic heart failure with preserved left ventricular ejection fraction in patients with hypertension and isolated mild diastolic dysfunction.
    Brzyżkiewicz H; Konduracka E; Gajos G; Janion M
    Pol Arch Med Wewn; 2016; 126(1-2):12-8. PubMed ID: 26810565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.